Hospital
Ochsner American Legion Hospital LLC
Ochsner American Legion Hospital LLC was paid $4.63M by Medicaid between Nov 2022 and Dec 2024, across 119 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoOCHSNER AMERICAN LEGION HOSPITAL LLC
JENNINGS, LA 70546
JENNINGS, LA 70546
33aNPI1184373268assigned 03/23/2022
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.63M
24GClaims102,462
24DCodes billed119
24AFirst – last monthNov 2022 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#51 of 96
Median peer was paid$5.17M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, DANA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 7,632 | $222K | |
| 2023 | 51,891 | $2.31M | |
| 2024incomplete | 42,939 | $2.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 5,021 | 4,684 | $1.49M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 3,012 | 2,697 | $1.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 4,651 | 4,396 | $654K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 1,570 | 1,199 | $132K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 955 | 883 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 2,223 | 1,646 | $85K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 1,801 | 1,677 | $60K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.3% | 634 | 552 | $58K |
| 80053 | Comprehensive metabolic panel | 1.3% | 7,720 | 6,861 | $58K |
| 80050 | General health panel | 1.2% | 1,414 | 1,321 | $55K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 247 | 224 | $55K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 1,964 | 1,751 | $54K |
107 more codes
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 1,621 | $48K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 1,609 | $48K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 1,614 | $48K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 8,383 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,014 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,201 | $39K |
| 80061 | Lipid panel | <1% | 3,308 | $37K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,601 | $31K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 936 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 948 | $30K |
| 87400 | <1% | 3,083 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,124 | $25K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 197 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,574 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 825 | $20K |
| 86780 | <1% | 1,683 | $19K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 502 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 190 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,099 | $15K |
| 76830 | Ultrasound, transvaginal | <1% | 154 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 439 | $13K |
| 87340 | <1% | 1,463 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 163 | $11K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 129 | $11K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 144 | $11K |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 177 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,144 | $10K |
| 87653 | <1% | 327 | $10K | |
| 86803 | <1% | 853 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,269 | $9K |
| 85027 | <1% | 1,331 | $7K | |
| 81025 | <1% | 1,055 | $7K | |
| 87088 | <1% | 893 | $6K | |
| 84484 | <1% | 842 | $5K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 12 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 44 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 668 | $4K |
| 83880 | <1% | 222 | $4K | |
| 86850 | <1% | 1,276 | $4K | |
| 86762 | <1% | 344 | $4K | |
| 71250 | <1% | 30 | $4K | |
| 81001 | <1% | 1,749 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 81 | $4K |
| 83021 | <1% | 204 | $3K | |
| 86787 | <1% | 288 | $3K | |
| 81003 | <1% | 1,821 | $3K | |
| 86702 | <1% | 251 | $3K | |
| 83020 | <1% | 207 | $2K | |
| 83690 | <1% | 510 | $2K | |
| 86003 | <1% | 148 | $2K | |
| 83735 | <1% | 628 | $2K | |
| 86900 | <1% | 1,278 | $2K | |
| 86901 | <1% | 1,287 | $2K | |
| 59025 | Fetal non-stress test | <1% | 18 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 890 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 309 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 301 | $2K |
| 82950 | <1% | 402 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 133 | $2K |
| 86701 | <1% | 250 | $2K | |
| C1769 | Guide wire | <1% | 15 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 723 | $1K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $1K |
| 87430 | <1% | 79 | $1K | |
| 87807 | <1% | 92 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 18 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $883.56 |
| 76937 | <1% | 15 | $867.53 | |
| 86592 | <1% | 252 | $829.74 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 27 | $810.00 |
| 82550 | <1% | 206 | $756.97 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 128 | $750.84 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 37 | $714.70 |
| 82553 | <1% | 159 | $684.21 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 15 | $681.35 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 18 | $646.00 |
| 85610 | <1% | 216 | $637.17 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 716 | $603.46 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 868 | $554.38 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 72 | $495.62 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 52 | $438.12 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 581 | $404.07 |
| 82105 | <1% | 27 | $402.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 45 | $384.32 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $346.92 |
| 85730 | <1% | 83 | $325.74 | |
| 82150 | <1% | 68 | $324.00 | |
| 80055 | <1% | 15 | $289.44 | |
| 82728 | <1% | 24 | $286.23 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 20 | $280.96 |
| 87486 | <1% | 14 | $280.72 | |
| 87581 | <1% | 14 | $280.72 | |
| 87081 | <1% | 49 | $271.83 | |
| 85384 | <1% | 36 | $254.66 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 17 | $203.54 |
| 83550 | <1% | 25 | $192.28 | |
| 80179 | <1% | 15 | $186.40 | |
| 99152 | <1% | 47 | $185.04 | |
| 85379 | <1% | 27 | $173.10 | |
| 84439 | <1% | 20 | $171.38 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 679 | $151.33 |
| 83540 | <1% | 25 | $142.34 | |
| 85007 | <1% | 55 | $126.17 | |
| 82785 | <1% | 23 | $115.22 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 303 | $63.31 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 17 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, DANA (CEO)
Parent organizationOCHSNER AMERICAN LEGION HOSPITAL LLC
| Provider | Location | Paid |
|---|---|---|
| Jennings American Legion Hospital, INC. | Jennings, LA | $5.26M |
| Jennings American Legion Hospital INC. | Jennings, LA | $5.05M |
| Jennings American Legion Hospital, INC. | Jennings, LA | $4.58M |
| Ochsner American Legion Hospital LLC | Jennings, LA | $4.26M |
| Ochsner American Legion Hospital LLC | Jennings, LA | $4.02M |
| Ochsner American Legion Hospital LLC | Eunice, LA | $2.96M |
| Jeter Speech Language Pathology Services, LLC | Shreveport, LA | $2.43M |
| Jennings American Legion Hospital INC | Lake Arthur, LA | $931K |
| Ochsner American Legion Hospital LLC | Lake Arthur, LA | $682K |
| Jennings American Legion Hospital, INC. | Jennings, LA | $143K |
| Ochsner American Legion Hospital LLC | Welsh, LA | $59K |
| Ochsner American Legion Hospital LLC | Jennings, LA | $45K |
| Jennings American Legion Hospital INC | Jennings, LA | $24K |
| Dana's Medical Transportation LLC | West Monroe, LA | $21K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.